Key takeaways
- R&D tax incentives can affect cash taxes, diligence, and exit value for private equity sponsors, even when they don’t drive the investment thesis
- Entity structure, taxable income, credit limitations, and deal structure can change who benefits from R&D credits and when those benefits become usable
- Documentation is becoming more important as buyers, advisors, and IRS reporting requirements put greater focus on business-component support
Private equity (PE) firms spend considerable time identifying opportunities to increase enterprise value and improve cash flow across their portfolios. (R&D) tax incentives rarely drive an investment thesis, but they can still affect taxes actually paid during ownership and create issues in acquisition or exit diligence.
The federal R&D credit under section 41 rewards companies that develop or improve products, software, manufacturing processes, formulas, techniques, and other business components.
Sections 174 and 174A govern the timing of deductions for research or experimental expenditures. Although these provisions are closely related, they serve different purposes. One creates a credit, while the others affect when deductions are recognized. For PE-backed companies, these provisions should be evaluated together because the combined impact often matters more than any one provision on its own.
For sponsors, the essential questions are practical:
- Where does the benefit reside?
- Can it be used during the hold period?
- How much actual tax does it reduce?
- Will the position withstand diligence?
- What will a buyer think about it at exit?



